TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

Therapeutics, Tools and Diagnostic Innovation

Close-up photograph of an array of beakers, one being filled with a liquid.

In 2022, biopharma companies broke new ground in previously untreated diseases, advanced new targeted cancer agents into the clinic, and continued to show the potential of novel modalities. Simultaneously, diagnostic, artificial intelligence (AI), and synthetic biology tools continue to change the face of how and when therapies are used, discovered, and manufactured. Cowen predicts that 2023 will see a deluge of data, trial starts, and commercial milestones as companies, providers, and payors assess the potential of these breakthroughs and how best to use them.


What we’re watching

  • Targeted Oncology
  • Epigenetics
  • Psychedelics
  • Targeted Protein Degredation (TPD)
  • MRD Monitoring
  • Alzheimer’s Disease
  • Diabetes and Obesity
  • RNA Therapies
  • Geographic Atrophy
  • FcRns
  • Synthetic Biology
  • Artificial Intelligence

At the heart of many health care advances will be AI and synthetic biology – tools that are rapidly being adopted across biopharma to improve efficiency.”

Cowen Research